Pulmonx (LUNG) Price to Sales (2020 - 2025)

Pulmonx (LUNG) has reported Price to Sales for 6 consecutive years, with 3.11 the latest figure, recorded in Q3 2025.

• On a quarterly basis, Price to Sales fell 80.65% year-over-year to 3.11 in Q3 2025; TTM through Sep 2025 was 0.73, a 82.34% decrease from a year earlier, with the FY2024 full-year figure at 3.22, down 54.91% from the prior year.
• Price to Sales was 3.11 for Q3 2025 at Pulmonx, down from 4.42 in the prior quarter.
• Over five years, Price to Sales peaked at 177.16 in Q1 2021 and troughed at 3.11 in Q3 2025.
• A 5-year average of 45.84 and a median of 25.47 in 2023 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales advanced 24.11% in 2023 and sank 80.65% in 2025, its largest moves.
• Over 5 years, Price to Sales stood at 86.4 in 2021, then plunged by 76.25% to 20.52 in 2022, then gained by 24.11% to 25.47 in 2023, then slumped by 55.38% to 11.37 in 2024, then tumbled by 72.66% to 3.11 in 2025.
• The last three Price to Sales figures came in at 3.11 (Q3 2025), 4.42 (Q2 2025), and 12.02 (Q1 2025), per Business Quant data.